These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 10926327

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma.
    Rey MJ, Fernández PL, Jares P, Muñoz M, Nadal A, Peiró N, Nayach I, Mallofré C, Muntané J, Campo E, Estapé J, Cardesa A.
    J Pathol; 1998 Mar; 184(3):265-71. PubMed ID: 9614378
    [Abstract] [Full Text] [Related]

  • 5. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
    Oda Y, Sakamoto A, Satio T, Kawauchi S, Iwamoto Y, Tsuneyoshi M.
    Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
    Giannikaki E, Kouvidou C, Tzardi M, Stefanaki K, Koutsoubi K, Gregoriou M, Zois E, Kakolyris S, Mavroudi C, Delides G, Georgoulias V, Kanavaros P.
    Anticancer Res; 1997 Sep; 17(3C):2123-7. PubMed ID: 9216675
    [Abstract] [Full Text] [Related]

  • 9. Interest of investigating p53 status in breast cancer by four different methods.
    Thirion A, Rouanet P, Thezenas S, Detournay D, Grenier J, Lopez-Crapez E.
    Oncol Rep; 2002 Sep; 9(6):1167-72. PubMed ID: 12375013
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up.
    Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek R, Morelli L, Palma PD, Harris AL, Barbareschi M.
    Clin Cancer Res; 1996 Sep; 2(9):1591-9. PubMed ID: 9816338
    [Abstract] [Full Text] [Related]

  • 12. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy.
    Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess H, Schlag PM, Dörken B, Daniel PT.
    J Clin Oncol; 2003 Sep 15; 21(18):3391-401. PubMed ID: 12885834
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S.
    J Am Coll Surg; 2004 Jan 15; 198(1):83-90. PubMed ID: 14698315
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M.
    Clin Cancer Res; 2005 Dec 01; 11(23):8348-57. PubMed ID: 16322295
    [Abstract] [Full Text] [Related]

  • 16. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis.
    Jiang M, Shao ZM, Wu J, Lu JS, Yu LM, Yuan JD, Han QX, Shen ZZ, Fontana JA.
    Int J Cancer; 1997 Oct 21; 74(5):529-34. PubMed ID: 9355976
    [Abstract] [Full Text] [Related]

  • 17. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
    Gorgoulis VG, Rassidakis GZ, Karameris AM, Papastamatiou H, Trigidou R, Veslemes M, Rassidakis AN, Kittas C.
    Mod Pathol; 1996 May 21; 9(5):544-54. PubMed ID: 8733770
    [Abstract] [Full Text] [Related]

  • 18. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z, Dalbagni G, Pohar KS, Yu G, Cordon-Cardo C.
    Clin Cancer Res; 2002 Jan 21; 8(1):171-9. PubMed ID: 11801555
    [Abstract] [Full Text] [Related]

  • 19. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma.
    Ito K, Sasano H, Matsunaga G, Sato S, Yajima A, Nasim S, Garret CT.
    J Pathol; 1997 Nov 21; 183(3):318-24. PubMed ID: 9422988
    [Abstract] [Full Text] [Related]

  • 20. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
    Bahnassy AA, Zekri AR, Abdallah S, El-Shehaby AM, Sherif GM.
    Pathol Int; 2005 Feb 21; 55(2):53-62. PubMed ID: 15693850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.